Novartis Announces Positive Results from Phase III IRIDIUM Study of Inhaled Combination QVM149 in Patients with Uncontrolled Asthma

Basel, September 30, 2019 – Novartis today announced that investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior to QMF149 (indacaterol acetate and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials